目的 探讨复方苦参注射液联合醋酸甲地孕酮治疗子宫内膜癌的临床疗效。方法 选取2013年4月-2015年8月在临高县人民医院妇产科接受治疗的子宫内膜癌患者88例,根据治疗方案的差别分为对照组和治疗组,每组各44例。两组患者均给予必要的基础治疗。对照组口服醋酸甲地孕酮片,160 mg/次,1次/d。治疗组在对照组基础上静脉滴注复方苦参注射液,20 mL加入0.9%生理盐水250 mL中,1次/d。两组患者均连续治疗4周。治疗后比较两组患者近期疗效,观察生存质量的改善和不良反应发生情况。结果 治疗后,对照组客观缓解率(ORR)为43.18%,临床获益率(CBR)为70.45%,治疗组ORR为65.91%,CBR为88.64%,两组ORR、CBR比较差异有统计学意义(P<0.05)。治疗后,对照组和治疗组生存质量改善率分别为75.00%和90.91%,差异具有统计学意义(P<0.05)。治疗过程中,对照组不良反应例数明显高于治疗组,差异具有统计学意义(P<0.05)。结论 复方苦参注射液联合醋酸甲地孕酮治疗子宫内膜癌效果显著,可显著改善患者生活质量,具有一定的临床推广应用价值。

Recently, the morbidity of breast cancer, ovarian cancer, pancreatic cancer, and other solid tumors has increased year by year, and there is still lack of effective drugs in clinic. As the first poly ADP-ribose polymerase inhibitor for human cancer therapy, preclinical studies show that rucaparib can significantly inhibit breast cancer, ovarian cancer, and other solid tumors. Clinical studies show that rucaparib has good safety and effectiveness. The drug situation, background, route of synthesis, preclinical, and clinical trials researches of rucaparib are reviewed in this paper.